Skip to main content
- Press releases

Asceneuron Joins CPAD Consortium

Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium

- Press releases

Asceneuron Expands Scientific Advisory Board

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

- Press releases

Abbas Hussain Appointed as Chair of Asceneuron

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

- Press releases

Asceneuron Welcomes Barbara Angehrn Pavik as New CEO

Asceneuron Welcomes Barbara Angehrn Pavik as New CEO as It Gears Up for Next Phase of Growth

- Event

Asceneuron to attend BIO International Convention in Boston

The Asceneuron team will attend the BIO International Convention to be held June 5-8 in Boston, MA.

- Event

Asceneuron will present at AD/PD 2023

The Asceneuron team will attend AD/PD 2023, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. from March 28th to April 1st, in Gothenburg, Sweden.

- Event

Asceneuron to attend Bio-Europe Spring event

Asceneuron's CEO Dirk Beher will attend the Bio Europe Spring partnering event held on March 20-22, 2023 in Basel, Switzerland.

- Press releases

Ferrer acquires worldwide rights to ASN90, exclusively to treat PSP

Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)

- Event

Asceneuron at the Annual Biotech in Europe Forum

Asceneuron will participate in the 22nd Annual Biotech in Europe Forum for global partnering and investment (BEF), being held on September 21st-22nd, 2022 in Basel.

- Event

Asceneuron at the Latsis Symposium

Asceneuron will present at the Latsis Symposium 2022 organised by the EPFL from August 31st to September 2nd, 2022 in Lausanne.